Proteasomal-dependent aggregate reversal and absence of cell death in a conditional mouse model of Huntington's disease

被引:122
|
作者
Martín-Aparicio, E
Yamamoto, A
Hernández, F
Hen, R
Avila, JS
Lucas, JJ [1 ]
机构
[1] Univ Autonoma Madrid, CSIC, Fac Ciencias, Ctr Biol Mol Severo Ochoa, E-28049 Madrid, Spain
[2] Columbia Univ, Ctr Neurobiol & Behav, New York, NY 10032 USA
来源
JOURNAL OF NEUROSCIENCE | 2001年 / 21卷 / 22期
关键词
Huntington's disease; aggregates; conditional transgenic mouse model; fast reversal; proteasome; absence of cell death;
D O I
10.1523/JNEUROSCI.21-22-08772.2001
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Neuronal intranuclear inclusions are a histopathological hallmark of Huntington's disease. Nevertheless, the precise mechanism by which they are formed and their relevance to neuronal cell death and/or dysfunction remains unclear. We recently generated a conditional mouse model of Huntington's disease (HD94) in which silencing expression of mutated huntingtin led to the disappearance of intranuclear aggregates and amelioration of the behavioral phenotype. Here, we analyze primary striatal neuronal cultures from HD94 mice to explore the dynamics of aggregate formation and reversal, the possible mechanisms involved, and the correlation between aggregates and neuronal death. In parallel, we examine symptomatic adult HD94 mice in similar studies and explored the relationship between aggregate clearance and behavioral reversal. We report that, in culture, aggregate formation and reversal were rapid processes, such that 2 d of transgene expression led to aggregate formation, and 5 d of transgene suppression led to aggregate disappearance. In mice, full reversal of aggregates and intranuclear mutant huntingtin was more rapid than reported previously and preceded the motor recovery by several weeks. Furthermore, the proteasome inhibitor lactacystin inhibited the aggregate clearance observed in culture, thus indicating that aggregate formation is a balance between the rate of huntingtin synthesis and its degradation by the proteasome. Finally, neither expression of the mutant huntingtin nor aggregates compromised the viability of HD94 cultures. This correlated with the lack of cell death in symptomatic HD94 mice, thus demonstrating that neuronal dysfunction, and not cell loss, triggered by mutant huntingtin underlies symptomatology.
引用
收藏
页码:8772 / 8781
页数:10
相关论文
共 50 条
  • [31] Studies of a knock-in mouse model of Huntington's disease
    Hickey, MA
    Thomasian, SE
    Gruen, E
    Zeitlin, S
    Li, XJ
    Faull, KF
    Levine, MS
    Chesselet, MF
    MOVEMENT DISORDERS, 2003, 18 (09) : 1091 - 1091
  • [32] Behavioural assessment of a mouse genetic model of Huntington's disease
    Johnston, HM
    Ennis, M
    Myers, RM
    Shelbourne, PF
    BRAIN RESEARCH, 1998, 809 (01) : A26 - A26
  • [33] Cardiac Dysfunction in the BACHD Mouse Model of Huntington's Disease
    Schroeder, Analyne M.
    Bin Wang, Huei
    Park, Saemi
    Jordan, Maria C.
    Gao, Fuying
    Coppola, Giovanni
    Fishbein, Michael C.
    Roos, Kenneth P.
    Ghiani, Cristina A.
    Colwell, Christopher S.
    PLOS ONE, 2016, 11 (01):
  • [34] Dantrolene is neuroprotective in Huntington's disease transgenic mouse model
    Xi Chen
    Jun Wu
    Svetlana Lvovskaya
    Emily Herndon
    Charlene Supnet
    Ilya Bezprozvanny
    Molecular Neurodegeneration, 6
  • [35] Altered dopaminergic function in a mouse model of Huntington's disease
    Dallérac, GM
    Milner, AJ
    Cummings, DM
    Vatsavayai, SC
    Hirst, MC
    Murphy, KPSJ
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2005, 76
  • [36] Imaging brain metabolism in a mouse model of Huntington's disease
    Farzana, Farheen
    McConville, Malcolm
    Hannan, Anthony
    Hatters, Danny
    Boughton, Berin
    PROTEIN SCIENCE, 2021, 30 : 27 - 27
  • [37] Metformin therapy in a transgenic mouse model of Huntington's disease
    Ma, Thong C.
    Buescher, Jessica L.
    Oatis, Benjamin
    Funk, Jason A.
    Nash, Andrew J.
    Carrier, Raeann L.
    Hoyt, Kari R.
    NEUROSCIENCE LETTERS, 2007, 411 (02) : 98 - 103
  • [38] ACMSD Provides Neuroprotection in a Mouse Model of Huntington's Disease
    Fink, K. D.
    Deng, P.
    Cameron, D.
    Brundin, L.
    Manfredsson, F. P.
    CELL TRANSPLANTATION, 2021, 30 : 5 - 6
  • [39] Therapeutic potential of erythropoietin in a mouse model of huntington's disease
    Rolfes, S.
    Boettcher, C.
    Priller, J.
    HUMAN GENE THERAPY, 2014, 25 (11) : A107 - A107
  • [40] Minocycline is not beneficial in a phenotypic mouse model of Huntington's disease
    Diguet, E
    Rouland, R
    Tison, F
    ANNALS OF NEUROLOGY, 2003, 54 (06) : 841 - 842